Phase II clinical studies of emibetuzumab in NSCLC patients with EGFR mutations (NCT01897480) and combination treatment with the anti-VEGFR2 mAb ramucirumab (NCT02082210) are ongoing. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.